Prelude Therapeutics (PRLD) Competitors $0.71 +0.01 (+1.54%) Closing price 04:00 PM EasternExtended Trading$0.70 0.00 (-0.55%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRLD vs. PRQR, TLSA, ACTU, EPRX, ENTA, TSVT, SCPH, MGNX, CGEN, and ALECShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include ProQR Therapeutics (PRQR), Tiziana Life Sciences (TLSA), Actuate Therapeutics (ACTU), Eupraxia Pharmaceuticals (EPRX), Enanta Pharmaceuticals (ENTA), 2seventy bio (TSVT), scPharmaceuticals (SCPH), MacroGenics (MGNX), Compugen (CGEN), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. ProQR Therapeutics Tiziana Life Sciences Actuate Therapeutics Eupraxia Pharmaceuticals Enanta Pharmaceuticals 2seventy bio scPharmaceuticals MacroGenics Compugen Alector Prelude Therapeutics (NASDAQ:PRLD) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, community ranking, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Do analysts recommend PRLD or PRQR? Prelude Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 465.85%. ProQR Therapeutics has a consensus price target of $9.17, suggesting a potential upside of 426.82%. Given Prelude Therapeutics' higher possible upside, equities analysts clearly believe Prelude Therapeutics is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Does the MarketBeat Community favor PRLD or PRQR? ProQR Therapeutics received 304 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 61.85% of users gave ProQR Therapeutics an outperform vote while only 49.18% of users gave Prelude Therapeutics an outperform vote. CompanyUnderperformOutperformPrelude TherapeuticsOutperform Votes3049.18% Underperform Votes3150.82% ProQR TherapeuticsOutperform Votes33461.85% Underperform Votes20638.15% Which has more volatility & risk, PRLD or PRQR? Prelude Therapeutics has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Is PRLD or PRQR more profitable? Prelude Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Prelude Therapeutics' return on equity of -66.89% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -66.89% -55.59% ProQR Therapeutics -134.31%-71.58%-19.70% Do institutionals and insiders hold more shares of PRLD or PRQR? 79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 62.8% of Prelude Therapeutics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer PRLD or PRQR? In the previous week, ProQR Therapeutics had 2 more articles in the media than Prelude Therapeutics. MarketBeat recorded 10 mentions for ProQR Therapeutics and 8 mentions for Prelude Therapeutics. ProQR Therapeutics' average media sentiment score of 0.81 beat Prelude Therapeutics' score of 0.75 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, PRLD or PRQR? ProQR Therapeutics has higher revenue and earnings than Prelude Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$3M12.97-$121.83M-$1.78-0.40ProQR Therapeutics$17.88M7.95-$30.43M-$0.32-5.44 SummaryProQR Therapeutics beats Prelude Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.90M$6.92B$5.61B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-0.406.1123.5218.73Price / Sales12.97223.52371.97119.64Price / CashN/A65.6738.0534.64Price / Book0.166.616.844.19Net Income-$121.83M$139.99M$3.19B$246.99M7 Day Performance-0.73%-2.46%5.28%-2.84%1 Month Performance-25.59%-9.02%-1.08%-10.76%1 Year Performance-84.70%-5.12%12.28%0.49% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics3.1521 of 5 stars$0.71+1.5%$4.00+465.9%-83.0%$38.90M$3M-0.40120Earnings ReportShort Interest ↓News CoveragePRQRProQR Therapeutics2.6381 of 5 stars$1.81-5.2%$9.17+406.4%-9.8%$147.84M$17.88M-5.66180Earnings ReportAnalyst UpgradeNews CoveragePositive NewsTLSATiziana Life Sciences1.3663 of 5 stars$1.40-17.2%N/A+191.8%$147.55MN/A0.008Short Interest ↓High Trading VolumeACTUActuate TherapeuticsN/A$7.34+5.6%N/AN/A$143.37MN/A0.0010EPRXEupraxia Pharmaceuticals2.6786 of 5 stars$3.99-4.2%$10.50+163.5%N/A$142.09MN/A-5.5429Gap DownENTAEnanta Pharmaceuticals4.4291 of 5 stars$6.66-7.8%$17.25+159.2%-50.0%$141.97M$66.59M-1.34160Short Interest ↓TSVT2seventy bio3.086 of 5 stars$2.71+1.7%$7.20+166.2%+4.7%$140.32M$45.62M-1.46440Upcoming EarningsAnalyst DowngradeNews CoverageSCPHscPharmaceuticals3.6224 of 5 stars$2.77-5.6%$15.00+442.5%-43.7%$139.36M$30.28M-1.4730High Trading VolumeMGNXMacroGenics4.1268 of 5 stars$2.21-2.9%$7.63+245.8%-86.5%$139.02M$139.77M-1.40430News CoverageCGENCompugen1.6954 of 5 stars$1.56-6.3%$4.00+157.2%-40.0%$138.76M$27.86M77.7570ALECAlector3.5724 of 5 stars$1.38-4.5%$3.50+154.5%-74.4%$136.24M$100.56M-0.81270 Remove Ads Related Companies and Tools Related Companies ProQR Therapeutics Alternatives Tiziana Life Sciences Alternatives Actuate Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Enanta Pharmaceuticals Alternatives 2seventy bio Alternatives scPharmaceuticals Alternatives MacroGenics Alternatives Compugen Alternatives Alector Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRLD) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
